Biomarkers.

Background: Three blood-based biomarkers of neurological injury-glial fibrillary acidic protein (GFAP), neurofilament light (Nf-L), and Tau-have emerged as promising biomarkers of neurological disorders and injuries such as hypoxic-ischemic encephalopathy (HIE), traumatic brain injury, and Alzheimer's disease (AD). The low levels of GFAP, Nf-L, and Tau in serum and plasma require highly sensitive assays to detect them. Here, we report the analytical validation of an ultrasensitive, electrochemiluminescence-based, multiplexed immunoassay for neurological biomarker assessment.

Developing Topics.

Background: TANGO was a Phase 2 clinical study designed to assess the safety and efficacy of gosuranemab, an anti-tau monoclonal antibody, in participants with mild cognitive impairment due to Alzheimer's disease (AD) or with mild AD dementia. Despite robust target engagement of unbound N-terminal tau, the clinical efficacy endpoint was not met. In this exploratory analysis of TANGO participants, we examine plasma p-tau217 levels to assess the feasibility of using this biomarker to identify patients with AD pathology and predict disease progression.

Drug Development.

Background: Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the formation of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) composed of tau aggregates. Research in animal models has generated hypotheses on the underlying mechanisms of the interaction between Aβ and tau pathology. In support of this interaction, results from clinical trials have shown that treatment with anti-Aβ monoclonal antibodies (mAbs) affects tau pathology.

Treatment of Pleural Mesothelioma: ASCO Guideline Update.

Purpose: To provide evidence-based recommendations to practicing physicians and others on the management of pleural mesothelioma (PM).

Methods: ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pathology, cancer genetics, and advocacy experts to conduct an updated literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2016 through 2024. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life.

Crises in Antimicrobial Stewardship: Misuse of Clarithromycin for Therapy.

is a class I carcinogen that infects more than 100 million individuals in the United States. Antimicrobial therapy for has typically been prescribed empirically rather than based on susceptibility testing. Until recently, therapeutic recommendations have generally ignored the principles of antibiotic stewardship.